Literature DB >> 16715419

Efficacy of continuous low-dose human atrial natriuretic peptide given from the beginning of cardiopulmonary bypass for thoracic aortic surgery.

Akira Sezai1, Motomi Shiono, Mitsumasa Hata, Mitsuru Iida, Shinji Wakui, Masao Soeda, Nanao Negishi, Yuji Kasamaki, Satoshi Saito, Jitsu Kato, Yukiyasu Sezai.   

Abstract

PURPOSE: Cardiac surgery performed under cardiopulmonary bypass (CPB) causes abnormalities of the renin-angiotensin-aldosterone system, resulting in decreased urine output and an accumulation of water in the third space. We studied the efficacy of continuous low-dose human atrial natriuretic peptide (hANP) in patients undergoing thoracic aortic surgery.
METHODS: We divided 40 patients undergoing thoracic aortic surgery into two groups: the hANP group, which received 0.02 microg/kg per minute of hANP and the non-hANP group, which did not. The hemodynamics, urine output, intensive care unit (ICU) and hospital stay, bleeding volume, homologous blood transfusion volume, furosemide dose, corrected KCl volume, and postoperative respiratory, hepatic, and renal function were compared in the two groups.
RESULTS: The urine output during CPB and from CPB weaning to return to ICU was significantly better in the hANP group. The bleeding volume, homologous blood transfusion volume, furosemide dose, and corrected KCl volume were all significantly less in the hANP group.
CONCLUSIONS: These findings support the consensus that hANP exerts its diuretic effects to their full potential when administered continuously at low doses during thoracic aortic surgery. We found it to be effective for postoperative hemostasis and for preventing ischemic reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715419     DOI: 10.1007/s00595-006-3194-9

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  13 in total

Review 1.  Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides.

Authors:  K Nakao; Y Ogawa; S Suga; H Imura
Journal:  J Hypertens       Date:  1992-09       Impact factor: 4.844

2.  Role of nitric oxide on atrial natriuretic peptide release induced by angiotensin II in superfused rat atrial tissue.

Authors:  H Soualmia; C Barthélemy; J Eurin; F Masson; A Carayon
Journal:  Regul Pept       Date:  2001-04-20

3.  Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction.

Authors:  M Hayashi; T Tsutamoto; A Wada; K Maeda; N Mabuchi; T Tsutsui; H Horie; M Ohnishi; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

4.  Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP).

Authors:  K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1984-01-13       Impact factor: 3.575

5.  Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs.

Authors:  T Maack; D N Marion; M J Camargo; H D Kleinert; J H Laragh; E D Vaughan; S A Atlas
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

6.  Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery.

Authors:  A Sezai; M Shiono; Y Orime; H Hata; M Hata; N Negishi; Y Sezai
Journal:  Ann Thorac Surg       Date:  2000-03       Impact factor: 4.330

7.  Hemodynamic effects of human atrial natriuretic peptide after modified Fontan procedure.

Authors:  T Hiramatsu; Y Imai; Y Takanashi; K Seo; M Terada; M Nakazawa
Journal:  Ann Thorac Surg       Date:  1998-03       Impact factor: 4.330

8.  Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans.

Authors:  A Chu; K G Morris; W D Kuehl; J Cusma; F Navetta; F R Cobb
Journal:  Circulation       Date:  1989-12       Impact factor: 29.690

9.  Effects of atrial natriuretic peptide in clinical acute renal failure.

Authors:  S N Rahman; G E Kim; A S Mathew; C A Goldberg; R Allgren; R W Schrier; J D Conger
Journal:  Kidney Int       Date:  1994-06       Impact factor: 10.612

10.  Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function.

Authors:  Y Saito; K Nakao; K Nishimura; A Sugawara; K Okumura; K Obata; R Sonoda; T Ban; H Yasue; H Imura
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

View more
  3 in total

Review 1.  Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis.

Authors:  Sagar U Nigwekar; Sankar D Navaneethan; Chirag R Parikh; John K Hix
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

Review 2.  Interventions for protecting renal function in the perioperative period.

Authors:  Mathew Zacharias; Mohan Mugawar; G Peter Herbison; Robert J Walker; Karen Hovhannisyan; Pal Sivalingam; Niamh P Conlon
Journal:  Cochrane Database Syst Rev       Date:  2013-09-11

3.  Strategies for post-cardiac surgery acute kidney injury prevention: A network meta-analysis of randomized controlled trials.

Authors:  Jia-Jin Chen; Tao Han Lee; George Kuo; Yen-Ta Huang; Pei-Rung Chen; Shao-Wei Chen; Huang-Yu Yang; Hsiang-Hao Hsu; Ching-Chung Hsiao; Chia-Hung Yang; Cheng-Chia Lee; Yung-Chang Chen; Chih-Hsiang Chang
Journal:  Front Cardiovasc Med       Date:  2022-09-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.